BioWorld - Wednesday, February 25, 2026

Amanda Lanier

Articles

ARTICLES

"IPOs" over dried and cracked earth
Med-tech financings August 2025

Med-tech financings hold steady through August, IPOs rebound

Sep. 9, 2025
By Amanda Lanier
Med-tech financings reached $20.21 billion in the first eight months of 2025, on par with the same period last year ($20.26 billion) and showing a strong recovery from the sector’s recent low in 2023 ($13.71 billion). The 2025 total is still well below the record-setting levels of 2020 ($41.83 billion) and 2021 ($38.72 billion).
Read More
Brain anatomy with financial data overlay
Index insights

Neurology biopharmas rebound on trial catalysts and Q2 gains

Sep. 5, 2025
By Amanda Lanier
No Comments
The BioWorld Neurological Diseases Index showed signs of recovery in August, narrowing its year-to-date decline to 14.31%, compared to a steeper drop of 22.34% at the end of May. Momentum shifted notably over the summer, with 17 of the 20 component companies posting gains between June and August. This marks a reversal from May, when 15 of the 20 stocks were in the red.
Read More
Index insights

Abcellera soars 121%, leads biopharma gainers on analyst buzz

Aug. 21, 2025
By Amanda Lanier
No Comments
The BioWorld Biopharmaceutical Index (BBI) showed signs of recovery after hitting its lowest point of the year in late May, when it closed the month down 7.02%. While still negative overall, the index improved to -5.11% by the end of June and finished July down 3.57%. Similarly, the Nasdaq Biotechnology Index and the Dow Jones Industrial Average bottomed out at the end of May but posted stronger rebounds, closing July up 3.49% and 3.73%, respectively.
Read More